David Chacko, M.D.

David is Chief Financial Officer and Chief Business Officer of Erasca, where he leads finance, investor relations, corporate and business development, and other functions. Bringing deep experience in strategy, finance, business development, and operations, he joined the company in 2019 as Chief Business Officer with oversight of its corporate and business development efforts and became Chief Financial Officer in 2020.

Prior to Erasca, he was a Principal at Versant Ventures, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. David joined Versant from Alcon, where, as Chief of Staff to the CEO, he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, David was an Engagement Manager at McKinsey, leading multiple teams serving pharmaceutical and medical device clients, across sales and marketing, R&D, finance, and other functions. Previously, David worked at SR One, Amgen, and Morgan Stanley.

David holds an M.D. from the University of Pennsylvania, where he was a Gamble Scholar and President of the medical student body, and an MBA from the Wharton School. He earned an MPhil from Oxford University as a Marshall Scholar, as well as undergraduate degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian.